Literature DB >> 12538495

Possible role of ceramide as an indicator of chemoresistance: decrease of the ceramide content via activation of glucosylceramide synthase and sphingomyelin synthase in chemoresistant leukemia.

Mitsuru Itoh1, Toshiyuki Kitano, Mitsumasa Watanabe, Tadakazu Kondo, Takeshi Yabu, Yoshimitu Taguchi, Kazuya Iwai, Masaro Tashima, Takashi Uchiyama, Toshiro Okazaki.   

Abstract

We investigated the possibility of the proapoptotic lipid ceramide as an indicator of chemoresistance in leukemia. Doxorubicin (DOX) increased the ceramide level and apoptosis in drug-sensitive HL-60 cells but not in drug-resistant HL-60/ADR cells, under the condition that the uptake of DOX was not different between the two cell lines. In addition, exogenous N-acetylsphingosine (C2-ceramide) enhanced DOX-induced apoptosis in HL-60/ADR cells without affecting the expression of multidrug resistant-1 protein (MDR 1) and the uptake of DOX. A lower level of ceramide with higher activities of glucosylceramide synthase (GCS) and sphingomyelin synthase (SMS) was detected in HL-60/ADR cells than in HL-60 cells. In contrast, HL-60/GCS cells, overexpressing GCS, significantly inhibited DOX-induced ceramide increase and apoptosis. These observations suggest the involvement of ceramide regulation in drug resistance of leukemia cells. In vivo, the level of ceramide was lower in chemoresistant leukemia patients (6.4 +/- 1.8 pmol/nmol phosphate; n = 14) than in chemosensitive patients (9.5 +/- 2.7 pmol/nmol phosphate; n = 9), and the activities of GCS and SMS were more than 2-fold higher in chemoresistant leukemia cells than in chemosensitive cells. MDR-1 protein was faintly expressed in one of four chemoresistant patients, but Bcl-2 were clearly detected in four patients. Therefore, it is suggested that a decrease of the ceramide level via activation of GCS and SMS is associated with the chemoresistant condition in leukemia, probably in relation to Bcl-2 but not to MDR-1 expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538495

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  55 in total

1.  Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells.

Authors:  Yong-Yu Liu; Gauri A Patwardhan; Kaustubh Bhinge; Vineet Gupta; Xin Gu; S Michal Jazwinski
Journal:  Cancer Res       Date:  2011-01-28       Impact factor: 12.701

Review 2.  Molecular pharmacodynamics in childhood leukemia.

Authors:  R Pieters; M L den Boer
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 3.  Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology.

Authors:  Lara Milane; Shanthi Ganesh; Shruti Shah; Zhen-Feng Duan; Mansoor Amiji
Journal:  J Control Release       Date:  2011-04-08       Impact factor: 9.776

4.  Multiple actions of doxorubicin on the sphingolipid network revealed by flux analysis.

Authors:  Justin M Snider; Magali Trayssac; Christopher J Clarke; Nicholas Schwartz; Ashley J Snider; Lina M Obeid; Chiara Luberto; Yusuf A Hannun
Journal:  J Lipid Res       Date:  2018-12-20       Impact factor: 5.922

5.  Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells.

Authors:  Li-Pin Kao; Samy A F Morad; Traci S Davis; Matthew R MacDougall; Miki Kassai; Noha Abdelmageed; Todd E Fox; Mark Kester; Thomas P Loughran; Jose' L Abad; Gemma Fabrias; Su-Fern Tan; David J Feith; David F Claxton; Sarah Spiegel; Kelsey H Fisher-Wellman; Myles C Cabot
Journal:  J Lipid Res       Date:  2019-07-30       Impact factor: 5.922

Review 6.  Ceramide glycosylation catalyzed by glucosylceramide synthase and cancer drug resistance.

Authors:  Yong-Yu Liu; Ronald A Hill; Yu-Teh Li
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

7.  Acid ceramidase as a therapeutic target in metastatic prostate cancer.

Authors:  Luz Camacho; Oscar Meca-Cortés; José Luis Abad; Simón García; Nuria Rubio; Alba Díaz; Toni Celià-Terrassa; Francesca Cingolani; Raquel Bermudo; Pedro L Fernández; Jerónimo Blanco; Antonio Delgado; Josefina Casas; Gemma Fabriàs; Timothy M Thomson
Journal:  J Lipid Res       Date:  2013-02-19       Impact factor: 5.922

8.  Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells.

Authors:  S Sobue; S Nemoto; M Murakami; H Ito; A Kimura; S Gao; A Furuhata; A Takagi; T Kojima; M Nakamura; Y Ito; M Suzuki; Y Banno; Y Nozawa; T Murate
Journal:  Int J Hematol       Date:  2008-02-20       Impact factor: 2.490

9.  Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and beta-catenin signaling.

Authors:  Yong-Yu Liu; Vineet Gupta; Gauri A Patwardhan; Kaustubh Bhinge; Yunfeng Zhao; Jianxiong Bao; Harihara Mehendale; Myles C Cabot; Yu-Teh Li; S Michal Jazwinski
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

10.  A new mixed-backbone oligonucleotide against glucosylceramide synthase sensitizes multidrug-resistant tumors to apoptosis.

Authors:  Gauri A Patwardhan; Qian-Jin Zhang; Dongmei Yin; Vineet Gupta; Jianxiong Bao; Can E Senkal; Besim Ogretmen; Myles C Cabot; Girish V Shah; Paul W Sylvester; S Michal Jazwinski; Yong-Yu Liu
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.